Quotient Limited Prices Initial Public Offering
April 25 2014 - 11:45AM
Quotient Limited ("Quotient") (Nasdaq:QTNTU), an established,
commercial-stage diagnostics company, today announced the pricing
of its initial public offering of 5,000,000 units, each consisting
of one ordinary share and one warrant to purchase 0.8 of one
ordinary share, at a price of $8.00 per unit. The warrants will be
exercisable at an exercise price of $8.80 per whole ordinary share.
In addition, Quotient has granted the underwriters a 30-day option
to purchase up to an additional 750,000 units at the initial public
offering price. All of the units are being offered by Quotient.
The units are expected to begin trading today, April 25, 2014,
on the NASDAQ Global Market under the ticker symbol "QTNTU." The
ordinary shares and warrants comprising the units will begin
trading separately on the NASDAQ Global Market under the symbols
"QTNT" and "QTNTW," respectively, on the first trading day
following the expiration of the underwriters' 30-day over-allotment
option, at which time trading of the units will be suspended and
the units will be delisted. The offering is expected to close on
April 30, 2014, pending customary closing conditions.
UBS Investment Bank, Baird and Cowen and Company are acting as
joint book-running managers for the offering.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission (SEC) on April 24, 2014. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Any offer or sale will be made only by means of a written
prospectus forming part of the effective registration statement.
When available, copies of the final prospectus may be obtained
from: UBS Investment Bank, Attention: Prospectus Department, 299
Park Avenue, New York, NY 10171, or by telephone at 1-888-827-7275;
or Robert W. Baird & Co. Incorporated, Attention: Syndicate
Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202,
Telephone: 800-792-2473 or email syndicate@rwbaird.com; or Cowen
and Company, LLC c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department,
Phone (631) 274-2806 / Fax (631) 254-7140.
About Quotient Limited
Quotient Limited is an established, commercial-stage diagnostics
company committed to reducing healthcare costs and improving
patient care through the development and commercialization of
innovative tests for blood grouping and serological disease
screening. Quotient is developing MosaiQTM, its proprietary
technology platform, to offer a breadth of diagnostic tests that is
unmatched by any commercially available transfusion diagnostic
instrument platform. Quotient's operations are based in Edinburgh,
Scotland; Newtown, Pennsylvania; and Eysins (near Geneva),
Switzerland.
CONTACT: Stephen Unger
stephen.unger@quotientbd.com
Quotient Limited - Unit (MM) (NASDAQ:QTNTU)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quotient Limited - Unit (MM) (NASDAQ:QTNTU)
Historical Stock Chart
From Nov 2023 to Nov 2024